UnitedHealth Group Incorporated (UNH)
NYSE · Healthcare · analysed October 14, 2026
UnitedHealth Group Incorporated is a diversified healthcare enterprise operating primarily through two business segments: UnitedHealthcare, which provides health benefits and insurance plans, and Optum, which delivers clinical care, pharmacy benefit management, and health data analytics services. Originally established in 1974 as Charter Med Incorporated and restructured as United HealthCare Corporation in 1977, the Minnetonka-based company has grown to become the largest healthcare organization in the United States by revenue. Currently, the company is focused on expanding value-based care delivery, integrating artificial intelligence and advanced technologies across its health platforms, and simplifying administrative workflows, including ongoing initiatives to streamline prior authorization requirements for care providers.
Executive summary
UnitedHealth Group commands an industry-leading position in U.S. managed care and pharmacy services through its vertically integrated UnitedHealthcare and Optum franchises8,22. Following severe industry-wide medical cost inflation in 2024 and 2025, the company demonstrated underwriting discipline by repricing contracts, shedding unprofitable membership, and raising full-year 2026 adjusted EPS guidance to at least $20.50 following a strong Q3 2026 beat7. While active Department of Justice inquiries into Medicare Advantage billing practices and federal scrutiny of pharmacy benefit managers create ongoing overhangs25,28,29, UnitedHealth's robust free cash flow, forward earnings recovery, and reasonable 16.8 forward P/E multiple position it favorably against depressed market expectations7.
Sources cited here, 6 of 29
- 7unitedhealthgroup.com
- 8csimarket.com
- 22ama-assn.org
- 25bracheichler.com
- 28federalregister.gov
- 29justice.gov
Key figures
- Market cap
- $339.8B
- P/E, trailing
- 24.3
- P/E, next 12 months
- 16.8
- Revenue growth, last fiscal year
- 11.8%
- Net margin, last fiscal year
- 2.7%
The full analysis adds sections on competition, financials and valuation, recent news, upcoming catalysts, institutional investors and fund letters. See the plans or join the waitlist.